You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

50 Results
Guidelines and Advice
Status: Current
ID: GL-C50-20
May 2015
Drug
Other Name(s): Provera® (multiple brands available)
Quick Link(s): Drug Monograph, Patient Info Sheet
Apr 2015
Guidelines and Advice
Status: Current
ID: GL-C50-19
Jan 2015
Drug
Other Name(s): Unituxin®
Quick Link(s): Drug Monograph
Jun 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia
Exceptional Access Program
    venetoclax - in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
venetoclax
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2023
Statistical Reports
Sep 2015
Statistical Reports
Sep 2015
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2023
Guidelines and Advice
Status: Current
ID: GL END 5-13
Version: N/A
Jun 2023
Guidelines and Advice
Status: Current
ID: PET 2022-2
Jun 2023
Guidelines and Advice
Status: In-Review
ID: 19-4
May 2015
Guidelines and Advice
Status: In-Review
ID: 15-12
Version: 2
Jan 2015

Pages